tbuckley/cabot-search huggingface dataset:
A7.7 Cognitive dysfunctions in patients with rheumatoid arthritis
Authors: S Monov, R Shumnalieva, D Monova, R Rashkov, Ek Chamurliiska
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (Rheumatoid Arthritis - RA) is a systemic, autoimmune, chronic inflammatory disease which involves mainly the musculoskeletal system in form of erosive arthritis (synovitis). According to different authors the incidence of extraarticular manifestations in RA is around 10–20%. The involvement of the central nervous system is rare in patients with RA and could be explained both by the disease itself (vasculitis, rheumatoid nodules, amyloidosis) or the treatment. The introduction of modern instrumental methods for investigation (hsCT, MRI, PET, SPECT) and tests for cognitive dysfunctions offers an opportunity for discovering the variety of neuropsychiatric disorders in patients with RA. <h3>Methods and Materials</h3> 96 patients with RA in the age range between 31 and 56 (mean 39.18 ± 6.13 years) were included in the study, of whom 78 were females and 18 – males with disease duration for 3 to 11 years (mean 5.45 ±1.6 years). Clinical tests for detecting cognitive dysfunctions were performed by a clinical psychologist to all patients. For excluding a possible cognitive dysfunction due to the corticosteroid treatment, the cognitive dysfunction of the patients with RA was compared with 225 patients with SLE, treated with corticosteroids and with the cognitive dysfunctions of 63 otherwise healthy individuals. <h3>Results</h3> In none of the patients there was a history for cognitive dysfunctions (memory, attention, thinking). Latent cognitive dysfunction was detected in 23 RA patients (23,96 %) with predominant disorders in the memory (47.83%). <h3>Conclusion</h3> Our study shows that the cognitive dysfunctions are significantly (p &lt; 0,001) more common in RA patients (23.96%) than in healthy individuals (17.46%), and, on the other hand, that the cognitive dysfunction in SLE patients (64.44%) is more demonstrative in comparison with RA patients independently of the long lasting steroid treatment in both groups (with similar data for the mean duration of the treatment and the mean dose of the drug). <h3>Keywords</h3> rheumatoid arthritis, extraarticular manifestations, cognitive dysfunctions
Abstract 310: Oncogene-specific regulation of immune responses during tumorigenesis
Authors: Vladislava Juric, Chunmei Wang, Xin Chen, J. Michael Bishop
Journal: Cancer Research (2012)

Abstract Oncogenes can induce inflammatory signaling, leading to the recruitment of immune cells to tumor site. Immune cells can further influence tumor development by either restraining or facilitating tumorigenesis. Here, we investigated how distinct oncogenes shape the immune responses during tumorigenesis in vivo. We utilized several established mouse models of liver cancer in which tumorigenesis is driven by the overexpression of MYC, MET, or AKT+RAS oncogenes. We evaluated the immune cells at early vs. late stages of tumor development by immunohistochemical staining of liver tissues using lineage-specific immune cell markers. In addition, we assessed activation of the pro-inflammatory NFκB pathway by immunoblot detection of IkBα and phospho-Ser(536)-NFκB levels in liver lysates, as well as by immunohistochemical analysis of NFκB (p65) nuclear localization. Histological analysis revealed leukocytic clustering around hepatocytes in pre-neoplastic livers in MYC and AKT+RAS, but not in the MET liver tumor model. Moreover, the leukocyte profiles identified in pre-neoplastic livers and liver tumors were different in MYC vs. AKT+RAS model. Finally, we found that the NFκB pathway was inactive in MYC and AKT+RAS tumors, but hyperactivated in MET tumors. In summary, our results suggest that the type of tumor-initiating oncogenic lesion profoundly influences the identity of recruited immune cells and activation of NFκB pathway in the course of tumorigenesis. We are currently in the process of elucidating the mechanisms behind oncogene-mediated regulation of immune responses, which may reveal novel targets for anti-cancer therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 310. doi:1538-7445.AM2012-310
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma
Authors: Wei Wei, Young Shik Shin, Min Xue, Tomoo Matsutani, Kenta Masui, Huijun Yang, Shiro Ikegami, Yuchao Gu, Ken Herrmann, Dazy Johnson, Xiangming Ding, Kiwook Hwang, Jungwoo Kim, Jian Zhou, Yapeng Su, Xinmin Li, Bruno Bonetti, Rajesh Chopra, C. David James, Webster K. Cavenee, Timothy F. Cloughesy, Paul S. Mischel, James R. Heath, Beatrice Gini
Journal: Cancer Cell (2016)
Continuation Maintenance Therapy with Pemetrexed(PEM) ± Bevacizumab(BEV) Following First Line Cisplatin/PEM ± BEV for NSCLC
Authors: T. Niwa, H. Yoshioka, Y. Kourogi, S. Ikeda, A. Nishiyama, M. Iwasaku, T. Ishida
Journal: Annals of Oncology (2013)
Reported Ant Re-sting Reaction in Thai Children with Ant Anaphylaxis Receiving Immunotherapy
Authors: P. Puranitee, S. Vilaiyuk, W. Kamchaisatian, W. Manuyakorn, W. Teawsomboonkit, C. Sasisakunporn, S. Benjaponpitak
Journal: Journal of Allergy and Clinical Immunology (2012)
EUS Preoperative Staging of Rectal Cancer for Transanal Endoscopic Microsurgery
Authors: Xia Lu, Dai Xin, Lin Mobin, Yin Lu, Zhu Qi
Journal: Endoscopy (2011)

Backgrounds and Aim: Transanal endoscopic microsurgery (TEM) offers a minimally invasive technique for the treatment of early carcinomas in selected patients and as a compromise treatment in patients unfit for major surgery. There is little knowledge of the value of endosonography (EUS) as a preoperative assessment tool for selecting rectal cancer patients who are benefit from TEM. In this study, we evaluated the sensitivity and the specificity of EUS in preoperative staging of rectal cancer to select appropriate candidates for TEM, instead of radical excision.
932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS
Authors: A.J.P. van der Meer, B.E. Hansen, J.J. Feld, H. Wedemeyer, J.-F. Dufour, F. Lammert, A. Duarte-Rojo, M.P. Manns, L. Kuske, S. Zeuzem, W.P. Hofmann, R.J. de Knegt, B.J. Veldt, H.L.A. Janssen
Journal: Journal of Hepatology (2012)
LIPOPROTEINS IN GENERAL AND CEREBRAL ARTERIOSCLEROSIS
Authors: ALEXANDER SIMON, JOHN W. GOFMAN, NATHAN MALAMUD, HARDIN B. JONES, FRANK T. LINDGREN
Journal: American Journal of Psychiatry (1952)

1. Lipoprotein levels (St 10-20 class) of a group of patients diagnosed as psychosis with cerebral arteriosclerosis display little significant difference from a group of normals of similar age. If the level of lipoproteins (St 10-20 class) is a reflection of the activity of atheroma formation, then these patients show no more atherosclerotic activity than presumably normal individuals of the same age. 2. The autopsy findings in 24 cases suggest that cerebral atherosclerosis plays an insignificant role in so-called psychosis with cerebral arteriosclerosis, the latter being due either to senile or arteriolosclerotic changes. There appears to be a trend to more "lipoidosis" as observed in the aorta, coronary, and cerebral vessels, with increasing levels of St 10-20 lipoproteins in the blood serum.
Forty years without symptoms after choledochogastrostomy
Authors: R. Schwarzer, A. Tischer, M. Dulic, E. Dulic-Lakovic, S. Assadi, M. Gschwantler
Journal: Endoscopy (2012)

The preferred surgical procedures for internal biliary drainage are choledocho(hepatico)jejunostomy and choledochoduodenostomy. Cholangiogastrostomy is not recommended because of the potential risk of bile gastritis, and because reflux of gastric fluid into the biliary tree could occur and cause complications in the long run. In addition, after cholangiogastrostomy anastomotic leakage would be of both bile and gastric juice, whereas after drainage into the small bowel the leakage would consist predominantly of bile. Cholangiogastrostomy by surgery, endoscopy, or by a combined fluoroscopic, endoscopic, and laparoscopic approach have been described [1] [2] [3]. However, these procedures were mostly used in patients with advanced malignant disease, and therefore data concerning the long-term risks of biliary drainage into the stomach are limited. To the best of our knowledge this is the first report about a patient who was free of symptoms during a follow-up period of several decades after choledochogastrostomy.
Oral Hydralazine Therapy for Primary Pulmonary Hypertension
Authors: Lewis J. Rubin, Robert H. Peter
Journal: New England Journal of Medicine (1980)

To evaluate the hemodynamic effects of hydralazine in four patients with primary pulmonary hypertension, we catheterized the right side of the heart before and 48 hours after starting therapy with oral hydralazine, 50 mg every six hours. Data were obtained at rest in four patients and also during exercise in three. After hydralazine, total pulmonary resistance at rest fell from 17.5 to 7.7 U, and pulmonary arteriolar resistance from 15.6 to 7.1 U; cardiac output increased from 3.8 to 7.1 liters per minute, and the arteriovenous oxygen difference narrowed from 7.8 to 5.4 ml per deciliter. Mean pulmonary and systemic arterial pressures were unchanged. Hydralazine also caused total pulmonary resistance during exercise to fall from 15.7 to 10.2 U, and cardiac output to rise from 4.7 to 7.0 liters per minute. Treatment was continued, and on repeat catheterizations three to six months later the hemodynamic effects persisted. These data suggest that hydralazine can reduce pulmonary resistance in some patients with idiopathic pulmonary hypertension. (N Engl J Med 302:69–73, 1980)
Abstract LB-58: Advocacy within the PS-OC: Evolution of the program
Authors: Carole L. Baas, Susan Samson
Journal: Cancer Research (2012)

Abstract The National Cancer Institute (NCI) has emphasized the importance of innovation and creativity in exploring strategies to control and eradicate cancer. This effort resulted in the formation of the Physical Sciences in Oncology program (PS-OC), which utilizes the fields of mathematics, physics, chemistry and engineering to address cancer. The NCI has sponsored a network of twelve PS-OC centers across the U.S. in an effort to have a cross-sectional evaluation of the physical principles used to study cancer. The PS-OC program aims to advance cancer research and move the research closer to practical application. A key instrument to move the research into clinical practice is the voice of patient advocates on the PS-OC research team. Patient advocacy has traditionally been focused on providing support and education for patients and stimulating research for better understanding of diseases and their treatment. The inclusion of patient advocates in the physical sciences is rare as the majority of advocates work in clinically-focused research and researchers in these fields seldom interact with advocates and patients. The PS-OC program has expanded the role of patient advocates to include involvement in basic and translational research in the physical sciences. The PS-OC advocacy program is a cooperative effort between the Centers and advocate advisors, who serve as liaisons between the patient and scientific communities. Each Center is developing an advocacy program unique to its research focus and the skills and interests of the advocate community. Advocates are an integral part of the scientific team, providing insight into clinical aspects of cancer; communicating research findings to the public through public lectures, lay articles and social media; presenting the patient perspective in university courses as guest speakers; and participating in legislative advocacy. However, the most important role of advocates is to provide the human element and perspective to the research. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-58. doi:1538-7445.AM2012-LB-58
Abstract 3236: Molecular characterization of lung tumors based on metabolomic profiling.
Authors: Daniel R. Sappington, Scott Helms, Ishwori B. Dhakal, Eric R. Siegel, Thaddeus Bartter, Gunnar Boysen
Journal: Cancer Research (2013)

Abstract Lung cancer is the leading cause of cancer-related deaths in US. For the majority of patients (70%), the extent of the disease precludes complete surgical resection and treatment relies solely on radiation, chemotherapy or a combination of both. Unfortunately, these treatments improve survival only minimally and are accompanied by considerable adverse side effects. Despite immense research efforts over the last 20 years, the mean survival of lung cancer patients has only increased by 13 days. This relatively poor mean survival is attributed to inadequate therapy selection. Current therapy selection is mainly based on the histopathologic examination of needle biopsies obtained during bronchoscopy. There is growing concern that these classifications and stratification are insufficient to predict treatment response of individual tumors. To complement current histopathological-based tumor classification, we investigated the suitability of metabolomics to improve tumor classification. Therefore, metabolomic profiles were obtained from various lung cancer cell-lines. Data were analyzed for molecular features characteristic for cell-lines derived from adenocarcinoma (AdenoCa) or squamous cell carcinoma (SqCCa). Data analyses revealed 78 features that are capable of clearly separating AdenoCa, SqCCa, and lung fibroblasts from each other. Subsequently, the studies were extended to specimen from 30 lung cancer patients. Similar to the cell-line experiments, metabolomic profiles were obtained and analyzed for characteristic features of patients with AdenoCa, SqCCa, or non-malignant specimen. The analysis of the human specimen revealed 21 unique features that are potentially suitable biomarkers for tumor classification. Our data suggest that metabolomic profiling is a promising approach to classify and distinguish between individual tumor cell-lines and to distinguish patients with AdenoCa from patients with SqCCa. Citation Format: Daniel R. Sappington, Scott Helms, Ishwori B. Dhakal, Eric R. Siegel, Thaddeus Bartter, Gunnar Boysen. Molecular characterization of lung tumors based on metabolomic profiling. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3236. doi:10.1158/1538-7445.AM2013-3236
AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION
Authors: A. Ghiaseddin, A. Dunn-Pirio, K. Peters, G. Vlahovic, J. Herndon, S. Threatt, J. Sampson, A. Friedman, H. Friedman, A. Desjardins
Journal: Neuro-Oncology (2014)

BACKGROUND: Two multicenter phase III trials, RTOG0825 and AVAglio, evaluated the addition of bevacizumab to RT and temozolomide in newly diagnosed glioblastoma patients and demonstrated a lack of statistically significant increased survival. In both studies, the majority of patients discontinued bevacizumab at the time of disease progression on bevacizumab. Given encouraging results in other diseases, we decided to evaluate the safety and benefit of incorporating bevacizumab from the time of diagnosis and throughout multiple treatment lines, beyond progression. METHODS: Patients with new diagnosis of WHO grade IV malignant glioma were enrolled on study after maximal safe surgical intervention. Patients were initiated on RT and temozolomide at 75 mg/m2/day, with bevacizumab at 10 mg/kg every 14 days beginning at least 28 days post-operatively. Following RT, patients initiated on adjuvant 5-day temozolomide for up to 12 cycles. Bevacizumab was maintained during adjuvant temozolomide, at tumor progression and once patients came off chemotherapy (maintenance phase). RESULTS: All planned 68 patients have been enrolled on study. Median age is 57.5 years and 69% are men. Two patients are still undergoing RT. At a median follow-up of 10.4 months, median progression-free survival was 9.9 months [95% confidence interval (CI), 8.7 months-not reached) and 1-year overall survival is 85.2% (95 CI, 70.9-92.8%). Grade 4 toxicities thus far include: neutropenia (n = 4); thrombocytopenia (n = 6); leucopenia (n = 3); colonic perforation (n = 1); sepsis (n = 1); intracranial hemorrhage (n = 1); and hypertension (n = 1). Grade 3 toxicities include: lymphopenia (n = 24); neutropenia (n = 6); thrombocytopenia (n = 9); leucopenia (n = 6); fatigue (n = 5); hypertension (n = 5); thromboembolic event (n = 3); and one each of anemia, elevated AST, ventricular tachycardia, oral mucositis, nausea, pustular rash, urinary tract infection, wound infection, cognitive difficulties, headaches, and allergic reaction. CONCLUSION: Continuing bevacizumab beyond progression is tolerable. Updated survival and toxicity results will be presented.
AB1287 Indocyanine green enhanced fluorescence optical imaging as a tool for quantifying the joint inflammation in collagen induced arthritis
Authors: M.I. Kang, K.H. Park, Y. Kang, S.W. Lee, S.K. Lee, Y.B. Park
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Imaging modality for quantitative assessment of inflammation in rheumatoid arthritis (RA) is needed for diagnosis and evaluation of treatment response. Magnetic resonance imaging and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) can be imaging modalities for quantitative assessment of inflammation, however, they have some limitations, such as, long examination time, high cost and the radiation exposure. Recently, fluorescence optical imaging (FOI) has been introduced as a fast and nonionizing imaging modality that offers high sensitivity for the detection of inflammatory arthritis <h3>Objectives</h3> This study was performed to evaluate the quantification of joint inflammation after treatment in collagen induced arthritis (CIA) mice using FOI. <h3>Methods</h3> To examine the feasibility of FOI to monitor the outcome of a therapeutic intervention, CIA mice were treated with methotrexate (MTX). Before and after treatment with MTX, FOI and <sup>18</sup>F-FDG PET analysis were performed. Quantitative analysis of the FOI scans was performed by measuring the fluorescence signal intensity of response to treatment via operator-defined regions of interest. <sup>18</sup>F-FDG injected in mice with CIA was analysed by PET <h3>Results</h3> ICG enhanced FOI showed a significant decrease in the fluorescence signal of arthritic joints of MTX treated mice at the time point of post-treatment compared with baseline values (p&lt;0.05). The fluorescence signal intensities of response to treatment were significantly associated with the clinical arthritis scores (p&lt;0.05). <sup>18</sup>F -FDG uptake was decreased after treatment similarly with FOI and clinical scores. <h3>Conclusions</h3> ICG enhanced FOI might be a useful tool for evaluating the quantification of joint inflammation <h3>References</h3> Irmler IM, et al. In vivo molecular imaging of experimental joint inflammation by combined <sup>18</sup>F-FDG positron emission tomography and computed tomography. Arthritis Res Ther 2010;12(6):R203. Meier R, et al. Indocyanine Green–Enhanced Imaging of Antigen-Induced Arthritis With an Integrated Optical Imaging/Radiography System. Arthritis Rheum 2010;62:2322-7. <h3>Disclosure of Interest</h3> None Declared
AB0417 Exercise is associated with decreased risk of metabolic syndrome in patients with sle
Authors: M. Ormseth, A. Oeser, C. M. Stein
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patients with systemic lupus erythematosus (SLE) have an increased prevalence of insulin resistance and the metabolic syndrome. Exercise has been shown to improve insulin resistance and components of the metabolic syndrome in the general population. However, few studies have evaluated the effects of exercise on the metabolic health of patients with SLE. <h3>Objectives</h3> Determine the relationship between exercise and metabolic health in SLE patients. <h3>Methods</h3> We performed a cross sectional study of 165 patients with SLE and recorded the amount of dedicated exercise performed outside of daily activities as metabolic equivalents in minutes per week (METs). We measured clinical variables, fasting insulin and glucose, and calculated the homeostasis model assessment (HOMA) as a measure of insulin resistance. Metabolic syndrome was defined by the National Cholesterol Education Program Adult Treatment Panel III definition. Current MET expenditure was categorized into quartiles and we used these to determine the relationship between exercise and the metabolic syndrome and its individual components using binary logistic regression and multivariable regression analyses adjusting for age, race and sex. <h3>Results</h3> Patients with SLE (n=165) had a median [IQR] age of 41 years [30-48], 89.1% were female, median BMI was 27.5 kg/m<sup>2</sup> [23.6-32.74], and 29% had metabolic syndrome. Median disease duration was 7 years [3-12] and SLEDAI was 4 [0-6]. The median exercise expenditure was 200 MET min/week [0-591.75]. With each quartile increase in METs, resting heart rate decreased by 2.3 beats per minute (95% CI, 0.7-4.0 beats per minute) (P=0.006). The odds of having metabolic syndrome was decreased by 25.9% (0.8-44.6%) for each quartile increase in METs (P=0.044). Each increasing quartile of exercise was associated with a 12.3% (0.2-22.9%) decrease in HOMA (P=0.045), 8.9 mg/dl (0.5-17.3 mg/dl) decrease in triglycerides (P=0.037), and 2.5 mg/dl (0.7-4.3 mg/dl) increase in HDL (P=0.006), but no significant change in the presence of hypertension (P=0.10), fasting glucose level (P=0.14), or BMI (P=0.11). There was a non-significant trend toward decreased waist circumference with increasing exercise (P=0.06). <h3>Conclusions</h3> Some metabolic benefits are associated with the amount of exercise performed in patients with SLE, particularly decreased odds of having metabolic syndrome and improvement in insulin resistance, triglyceride, and HDL levels. Future interventional studies to determine if exercise can prevent or reverse the metabolic syndrome and its associated adverse cardiometabolic risk factors in patients with SLE patients will be of interest. <h3>Disclosure of Interest</h3> None Declared